53 -11 (83) 2025 - Ortikboev J.O. - OPTIMIZATION OF METHODS FOR PREVENTING THE PROGRESSION OF THE CLINICAL COURSE OF CHRONIC KIDNEY DISEASE

OPTIMIZATION OF METHODS FOR PREVENTING THE PROGRESSION OF THE CLINICAL COURSE OF CHRONIC KIDNEY DISEASE

Ortikboev J.O. - Tashkent State Medical University

Resume

A prospective randomized open-label controlled trial was conducted, which included 150 patients with CKD stages 3-4 (GFR 15-59 ml/min/1.73 m2). The patients were randomized into 2 groups: the main group (n=75), which received an optimized program (an individualized low-protein diet of 0.6-0.8 g/kg/day under the control of nutritional status, strict blood pressure control (<130/80 mmHg) with priority of ace inhibitors/ARBs, correction of phosphorus-calcium metabolism, anemia treatment, the patient's school), and a comparison group (n=75) who received standard therapy according to national guidelines. The follow-up period was 24 months. The main criterion of effectiveness was the rate of decrease in glomerular filtration rate (GFR, ml/min/1.73 m2/year). Additional criteria included the dynamics of proteinuria, serum albumin levels, and the frequency of achieving target blood pressure, phosphorus, and hemoglobin levels.

Keywords: chronic kidney disease, progression, prevention, glomerular filtration rate, proteinuria, arterial hypertension, diet therapy, phosphorus-calcium metabolism, anemia.

First page

305

Last page

310

For citation:Ortikboev J.O. - OPTIMIZATION OF METHODS FOR PREVENTING THE PROGRESSION OF THE CLINICAL COURSE OF CHRONIC KIDNEY DISEASE//New Day in Medicine 11(85)2025 305-310 https://newdayworldmedicine.com/en/new_day_medicine/11-85-2025

List of References

1. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet . 2020;395(10225):709-733.
2. Jha V., Garcia-Garcia G., Iseki K., et al. Chronic kidney disease: global dimension and perspectives. The Lancet . 2013;382(9888):260-272.
3. Levin A., Stevens P.E., Bilous R.W., et al. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl . 2013;3(1):1-150.
4. Remuzzi G., Benigni A., Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest . 2006;116(2):288-296.
5. Drawz P., Rahman M. Chronic kidney disease. Ann Intern Med . 2015;162(11):ITC1-ITC16.
6. Ruggenenti P., Perna A., Remuzzi G.; GISEN Group Investigators. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int. 2003;63(6):2254-2261.
7. Heerspink H.J.L., Kröpelin T.F., Hoekman J., et al. Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis. J Am Soc Nephrol. 2015;26(8):2055-2064.
8. Garneata L., Stancu A., Dragomir D., et al. Ketoanalogue-Supplemented Vegetarian Very Low–Protein Diet and CKD Progression. J Am Soc Nephrol. 2016;27(7):2164-2176.
9. Palmer S.C., Ruospo M., Natale P., et al. Phosphate-binding agents for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev. 2018;8(8):CD006023.
10. Locatelli F., Nissenson A.R., Barrett B.J., et al. Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2008;74(10):1237-1240.

    file

    download